mTOR signaling for biological control and cancer
- PMID: 23460185
- PMCID: PMC4491917
- DOI: 10.1002/jcp.24351
mTOR signaling for biological control and cancer
Abstract
Mammalian target of rapamycin (mTOR) is a major intersection that connects signals from the extracellular milieu to corresponding changes in intracellular processes. When abnormally regulated, the mTOR signaling pathway is implicated in a wide spectrum of cancers, neurological diseases, and proliferative disorders. Therefore, pharmacological agents that restore the regulatory balance of the mTOR pathway could be beneficial for a great number of diseases. This review summarizes current understanding of mTOR signaling and some unanswered questions in the field. We describe the composition of the mTOR complexes, upstream signals that activate mTOR, and physiological processes that mTOR regulates. We also discuss the role of mTOR and its downstream effectors in cancer, obesity and diabetes, and autism.
Copyright © 2013 Wiley Periodicals, Inc.
Similar articles
-
The expanding role of mTOR in cancer cell growth and proliferation.Mutagenesis. 2015 Mar;30(2):169-76. doi: 10.1093/mutage/geu045. Mutagenesis. 2015. PMID: 25688110 Free PMC article. Review.
-
Mammalian target of rapamycin: a central node of complex signaling cascades.Int J Clin Exp Pathol. 2011 Jun 20;4(5):476-95. Epub 2011 Jun 14. Int J Clin Exp Pathol. 2011. PMID: 21738819 Free PMC article. Review.
-
The mTOR signalling pathway in human cancer.Int J Mol Sci. 2012;13(2):1886-1918. doi: 10.3390/ijms13021886. Epub 2012 Feb 10. Int J Mol Sci. 2012. PMID: 22408430 Free PMC article. Review.
-
Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival.Exp Eye Res. 2015 Jun;135:1-13. doi: 10.1016/j.exer.2015.04.006. Epub 2015 Apr 14. Exp Eye Res. 2015. PMID: 25887293 Free PMC article.
-
mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.FASEB J. 2013 May;27(5):1796-807. doi: 10.1096/fj.12-222224. Epub 2013 Jan 25. FASEB J. 2013. PMID: 23355268 Free PMC article. Review.
Cited by
-
Mitigation of Breast Cancer Cells' Invasiveness via Down Regulation of ETV7, Hippo, and PI3K/mTOR Pathways by Vitamin D3 Gold-Nanoparticles.Int J Mol Sci. 2024 May 14;25(10):5348. doi: 10.3390/ijms25105348. Int J Mol Sci. 2024. PMID: 38791386 Free PMC article.
-
Analysis of HIF-1α expression and genetic polymorphisms in human clear cell renal cell carcinoma.Pathol Oncol Res. 2024 Jan 11;29:1611444. doi: 10.3389/pore.2023.1611444. eCollection 2023. Pathol Oncol Res. 2024. PMID: 38273861 Free PMC article.
-
Newly Synthesized Anticancer Purine Derivatives Inhibiting p-EIF4E Using Surface-Modified Lipid Nanovesicles.ACS Omega. 2023 Oct 6;8(41):37864-37881. doi: 10.1021/acsomega.3c02991. eCollection 2023 Oct 17. ACS Omega. 2023. PMID: 37867723 Free PMC article.
-
Regulation of mRNA translation by estrogen receptor in breast cancer.Steroids. 2023 Dec;200:109316. doi: 10.1016/j.steroids.2023.109316. Epub 2023 Oct 6. Steroids. 2023. PMID: 37806603 Review.
-
Inhibition of ERK signaling for treatment of ERRα positive TNBC.PLoS One. 2023 May 10;18(5):e0283047. doi: 10.1371/journal.pone.0283047. eCollection 2023. PLoS One. 2023. PMID: 37163498 Free PMC article.
References
-
- Barilli A, Visigalli R, Sala R, Gazzola GC, Parolari A, Tremoli E, Bonomini S, Simon A, Closs EI, Dall’Asta V, Bussolati O. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res. 2008;78:563–571. - PubMed
-
- Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630–2637. - PubMed
-
- Baselga J, Campone M, Piccart M, Burris HA, III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–529. - PMC - PubMed
-
- Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F, Xia J, Casanova E, Costa CF, Brink M, Zorzato F, Hall MN, Ruegg MA. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 2008;8:411–424. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous